| Autor: |
Hampel PJ; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Rabe KG; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Wang Y; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Hwang SR; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Kenderian SS; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Leis JF; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA., Koehler AB; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Tsang M; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA., Parrondo R; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA., Bailen RJ; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Schwager SM; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Hanson CA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Braggio E; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA., Slager SL; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Shi M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Zepeda-Mendoza CJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Van Dyke DL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Shanafelt TD; Division of Hematology, Department of Medicine, Stanford University, Palo Alto, CA, USA., King RL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Call TG; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Kay NE; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Ding W; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Parikh SA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. parikh.sameer@mayo.edu. |
| Abstrakt: |
Competing Interests: Competing interests: The authors declare no competing financial interests in direct relation to the work reported. The following authors also declare no competing financial interests otherwise: PJH, KGR, SRH, JFL, RP, RJB, SMS, MT, CAH, MS, CJZM, DLV, EB, SLS, RBK, TGC. In the interest of transparency, additional potential conflicts of interest for the remaining authors are included below. TH: Consultancy for BeiGene. Research funding provided to the institution from BeiGene. YW: Membership on Board of Directors or advisory committees for Incyte, InnoCare, LOXO Oncology, Eli Lilly, TG Therapeutics, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie (compensation to institution). Research funding (to institution) from Incyte, InnoCare, LOXO Oncology, Eli Lilly, Novartis, Genentech, MorphoSys, GenMab, AbbVie. Honorarium (to institution) from Kite. SSK: Patents and royalties from Novartis, Humanigen, Mettafforgr, Sendero, and MustangBio; Research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen; Scientific advisory boards in Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, and Novartis; DSMB: Humanigen, Carisma; Consultancy: Torque, Calibr, Novartis, Capstan Bio, and Humanigen. EM: Honorarium from Janssen. Consultation fee from Protego (paid to the institution). SA: Consultancy for BMS, Janssen, Amgen, Pharmacyclics, GSK, Takeda, Genentech, AbbVie, Karyopharm, Beigene, Sanofi. Research funding from BMS, Janssen, Amgen, Pharmacyclics, Ascentage, Medimmune, Cellectar, Xencor, GSK. ABK: Membership on Board of Directors or advisory committees for AbbVie and TG Therapeutics. TDS: Research funding from Abbvie, Genentech, and Pharmacyclics. NEK: Membership on Board of Directors or advisory committees for Abbvie, BMS, Celgene, Pharmacyclics, AstraZeneca, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Targeted Oncology, Agios Pharm, Morpho-sys, Rigel. Research funding from Abbvie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. WD: Employment with BeiGene. Research funding has been provided to the institution from Merck and DTRM. Participation in advisory board meetings for Merck and Octapharma. SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, Ascentage Pharma, Eli Lilly, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings. |
Full text from SpringerLink